Lonza extends collaboration with Biopharma company
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
It is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
Subscribe To Our Newsletter & Stay Updated